Changchun Lajiang Pharmaceutical Technology

Changchun Lajiang Pharmaceutical Technology is a Chinese biotechnology company focused on the development of innovative small molecule therapeutics for metabolic diseases. The company specializes in the discovery of multi-agonist treatments targeting the GLP-1, GIP, and glucagon receptors to address conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging advanced medicinal chemistry, Lajiang aims to create oral alternatives to existing injectable peptide therapies. The firm operates primarily within the domestic Chinese market while seeking to advance its pipeline through early-stage research and development.